Jan. 23, 2013
/PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL), a specialty biopharmaceutical company ("Auxilium"), today announced that it intends, subject to market and other conditions, to offer
aggregate principal amount of Convertible Senior Notes due 2018 (the "Convertible Notes") in an offering (the "Offering") registered under the Securities Act of 1933, as amended (the "Securities Act"). The Convertible Notes are expected to pay interest semi-annually and be convertible into shares of Auxilium's common stock, cash or a combination thereof at Auxilium's election.
Goldman, Sachs & Co. and J.P. Morgan Securities LLC are acting as joint book-running managers for the Offering.
Cowen and Company and RBC Capital Markets are acting as co-managers for the Offering. The Convertible Notes will be offered and sold under Auxilium's shelf registration statement on Form S-3 filed with the Securities and Exchange Commission (the "SEC") on
January 23, 2013
, which was effective upon filing, and a preliminary prospectus supplement setting forth the terms of the Convertible Notes, filed with the SEC on
January 23, 2013
. Before investing, investors should read the prospectus and the preliminary prospectus supplement and other documents that Auxilium has filed with the SEC for more complete information about Auxilium and the Offering. These documents may be obtained at
. Printed copies of the preliminary prospectus supplement relating to the Offering may also be obtained by requesting copies from Goldman, Sachs & Co. (Attn: Prospectus Department, 200 West Street,
New York, New York
10282, Fax: 212-902-9316 or Email at
or by calling 1-866-471-2526) or J.P. Morgan Securities LLC (c/o Broadridge Financial Solutions, 1155 Long Island Avenue,
11717 or by calling 866-803-9204).
The Convertible Notes will be general senior unsecured obligations of Auxilium.